Clonal haematopoiesis in chronic lymphocytic leukaemia: Biology, inflammaging and clinical implications in the era of targeted therapy - PubMed
3 days ago
- #targeted therapy
- #clonal haematopoiesis
- #chronic lymphocytic leukaemia
- Clonal haematopoiesis (CH) is an age-related condition relevant in haematologic malignancies, including chronic lymphocytic leukaemia (CLL).
- CH in CLL is associated with genomic instability, chronic inflammation, and immune system alterations, influencing disease biology.
- CH may impact prognosis, treatment-related toxicities, cardiovascular risk, and predispose to therapy-related myeloid neoplasms in CLL patients.
- Targeted therapies like BTK and BCL2 inhibitors interact differently with CH compared to chemoimmunotherapy, potentially mitigating adverse effects.
- Integrating CH assessment into CLL management could improve risk stratification and long-term survivorship strategies.
- Further studies are needed to clarify CH's prognostic value and integrate its assessment into clinical practice.